NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--May 15, 2006--BrainStorm Cell Therapeutics (OTCBB:BCLI - News), the developer of NurOwn(TM) bone marrow-derived-stem cell therapeutic products for the treatment of neurodegenerative diseases, announced today that the company has appointed Haim Nissenson as strategic financial consultant.
